Supplementary Data. The Seller will provide the Buyer with data supplementary to the Provisioning Data, comprising local manufacture tables, ground support equipment, specific-to-type tools and a pool item candidate list.
Supplementary Data. The Seller will provide the Buyer with Local Manufacture Tables (X-File), as part of the Illustrated Parts Catalog (Additional Cross-Reference Tables), which will be a part of the Initial Provisioning Data Package.
Supplementary Data. The Seller shall provide the Buyer with supplementary data to the Initial Provisioning Data, including Local Manufacture Tables (X-File) and Ground Support Equipment and Specific (To-Type) Tools (W-File) in accordance with SPEC 2000, Chapter 1.
Supplementary Data. AirPlus may provide supplementary information about transactions if Customer requested the provision of such on the Account application. AirPlus cannot provide such supplementary data without the cooperation of Customer’s travel agent(s), and Customer will need to make arrangements with its travel agent(s) for the provision of the services necessary for AirPlus to provide the supplementary data. However, Customer shall not be entitled to withhold payment from AirPlus on the grounds that any supplementary data does not appear on Customer’s statement or appears to be incorrect.
Supplementary Data. The Seller will provide the Buyer with Local Manufacture Tables (X-File), and Ground Support Equipment and Specific to-type Tools (W-File) and a Pool Item Candidate List (Y-File) as a part of the Initial Provisioning Data package.
Supplementary Data. The Seller shall provide the Buyer with data supplementary to the Provisioning Data, comprising local manufacture tables, ground support equipment, specific-to-type tools and a pool item candidate list. The list of spare parts required for the installation of all airframe LRUs will be provided by the Seller to the Buyer during the Initial Provisioning Conference
Supplementary Data. Genotoxicity Aside the NANoREG project, the genotoxicity of NM103 and NM104 was tested in vitro on Caco2 cells for concentrations up to 256 μg/ml during a bilateral ANR/DFG project between France and Germany (SolNanoTox) with both, the comet assay modified with FpG enzyme for detection of oxidized bases and the micronucleus assay. The outcomes are presented in table 1. TEST NM103 NM104 COMET ASSAY Negative Negative COMET ASSAY +FpG Negative Negative MICRONUCLEUS ASSAY Negative* Negative* *due to the interference with the assay (NPs masking the cytoplasm and the potential presence of micronuclei) it cannot be conclude that no induction of micronuclei occurred at the highest concentrations tested. Table 1: Response of differentiated Caco2 cells on exposure towards NM103 and 104 for 24h
Supplementary Data. Any Supplementary Data required for the Design can be obtained from the below mentioned Data. Design Speed 65 kmph Chemical Contents of Subsoil and Subsoil Work Sulphate Content in Soil Sulphate Content in Water Contractor shall verify the Conditions Chloride Content in Soil Chloride Content in Water Temperature Range 170C
Supplementary Data. Figure S1. Age at breast cancer development (black bars) and ovarian cancer development (grey bars) for the carriers of BRCA1*R1699Q. Figure S2. Cumulative risks (%) for breast cancer (left graph) and ovarian cancer (right graph) by age for carriers of BRCA1*R1699Q based on the main analysis (blue line), sub-analysis 1 (orange line) and sub-analysis 2 (purple line). The corresponding curves or the cumulative risk conferred by average pathogenic BRCA1 variants (red line) and for the general population (green line) are also shown. Cumulative risks are calculated using segregation analysis, major gene model assuming constant relative risk. Figure S3. Cumulative risks (%) for breast cancer (left graph) and ovarian cancer (right graph) by age for carriers of BRCA1*R1699Q based on the main analysis (blue line), sub-analysis 1 (orange line) and sub-analysis 2 (purple line). The corresponding curves or the cumulative risk conferred by average pathogenic BRCA1 variants (red line) and for the general population (green line) are also shown. Cumulative risks are calculated using segregation analysis, major gene model assuming relative risk as a continuous, piecewise linear function of age. Table S1. Number and origin of families in the previous study and current study (previous plus newly included families) . Previous study10 Current study Country # Families # Families with additional genotyping (*) # Families # Families with additional genotyping (*) The Netherlands 12 3 20 15 Denmark 10 4 22 19 France 5 3 14 7 Germany 5 1 19 10 South Africa 1 1 1 1 Sweden 14 5 20 17 United Kingdom 4 2 4 2 U.S.A. 9 7 14 11 Total 69 30 129 91 (*): additional genotyping means at least one other relative tested in addition to the index. Table S2. Descriptive characteristics of the 129 families. Unknown Carriership Non-carriers Carriers Age Total BC# OC& Total BC OC Total BC OC <30 2935 1 0 100 0 0 105 4 0 30-39 89 18 2 8 1 0 37 26 1 40-49 94 26 5 27 5 0 60 39 8 50-59 124 40 26 24 4 1 53 30 24 60-69 122 36 15 6 2 0 39 11 12 70-79 96 16 7 4 2 1 11 3 6 >=80 82 10 2 4 1 0 4 0 1 Total 3542 147 57 173 15 2 309 113 52 #BC: Breast cancer &OC: Ovarian cancer 3 Table S3. Cumulative risk (95% Confidence Interval) using segregation analysis, major gene models assuming constant relative risk. Main Analysis Cumulative risk (95% Confidence Interval) Sub-Analysis 1 Cumulative risk (95% Confidence Interval) Sub-Analysis 2 Cumulative risk (95% Confidence Interval) Age Breast cancer Ovarian cancer Breast ...
Supplementary Data. (3.0)%====== (6.1)%====== (7.8)%====== EBITDA(1)................................................. 16.4% 10.6% 9.7% ---------------
